Compare NICM & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NICM | LUNG |
|---|---|---|
| Founded | 1980 | 1995 |
| Country | Canada | United States |
| Employees | 25 | N/A |
| Industry | | Industrial Specialties |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.4M | 97.1M |
| IPO Year | N/A | 2020 |
| Metric | NICM | LUNG |
|---|---|---|
| Price | $5.06 | $2.91 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.70 |
| AVG Volume (30 Days) | 4.6K | ★ 1.2M |
| Earning Date | 11-27-2026 | 10-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $90,497,000.00 |
| Revenue This Year | $355.99 | $0.33 |
| Revenue Next Year | $161.43 | $8.68 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $4.71 | $1.13 |
| 52 Week High | $7.00 | $3.25 |
| Indicator | NICM | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 45.84 | 63.79 |
| Support Level | $4.71 | $1.26 |
| Resistance Level | $5.68 | $3.25 |
| Average True Range (ATR) | 0.25 | 0.34 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 20.59 | 75.34 |
Nicola Mining Inc is a junior exploration and custom milling company that is engaged in the business of identification, acquisition, and exploration of mineral property interests, together with custom milling partnerships at its Merritt Mill. The company holds interests in various claims at the following properties: the Treasure Mountain Property, New Craigmont Property, and Dominion Creek Property. Its portfolio of producing assets and development projects is mainly composed of copper, gold, and silver properties spread across British Columbia, Canada.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.